Long term exposure to norharman exacerbates 6-hydroxydopamine-induced parkinsonism: Possible involvement of L-type Ca2+ channels

Behavioural Brain Research

Volumn 215, Issue 1, 2010, Pages 136-140

  Haghdoost Yazdi, Hashem ^a   Hosseini, Sedighe Sadat ^a   Faraji, Ayda ^a   Nahid, Delaram ^a   Jahanihashemi, Hassan ^a  

^a QAZVIN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

6 OHDA; BCs; Behavioral symptoms; Nifedipine; Norharman; Parkinson's disease

Indexed keywords

BETA CARBOLINE; CALCIUM CHANNEL L TYPE; NIFEDIPINE; OXIDOPAMINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DISEASE EXACERBATION; DOPAMINERGIC NERVE CELL; LONG TERM EXPOSURE; MALE; NERVE CELL NECROSIS; NEUROTOXICITY; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; PROTEIN FUNCTION; RAT; SUBSTANTIA NIGRA;

ANALYSIS OF VARIANCE; ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; HARMINE; MALE; NEURONS; NIFEDIPINE; OXIDOPAMINE; PARKINSON DISEASE, SECONDARY; RATS; RATS, WISTAR;

EID: 77955846667     PISSN: 01664328     EISSN: 18727549     Source Type: Journal    
DOI: 10.1016/j.bbr.2010.07.011     Document Type: Article

References (35)

1. Adell A., Biggs T.A., Myers R.D. Action of harman 1-methyl-b-carboline on the brain: body temperature and in vivo efflux of 5-HT from hippocampus of the rat. Neuropharmacology 1996, 35:1101-1107.
2. Baum S.S., Hill R., Rommelspacher H. Harman-induced changes of extracellular concentrations of neurotransmitters in the nucleus accumbens of rats. Eur J Pharmacol 1996, 314:75-82.
3. Bonnet R., Pavlovic S., Lehmann J., Rommelspacher H. The strong inhibition of triosephosphate isomerase by the natural-carbolines may explain their neurotoxic actions. Neuroscience 2004, 127:443-453.
4. Chan C.S., Gertler T.S., Surmeier D.J. Calcium homeostasis, selective vulnerability and Parkinson's disease. Trends Neurosci 2009, 32(5):249-256.
5. Collins M.A., Neafsey E.J., Matsubara K., Cobuzzi R.J., Rollema H. Indole-N-methylated-carbolinium ions as potential brain-bioactivated toxins. Brain Res 1992, 505:154-160.
6. Collins M.A., Neafsey E.J., Matsubara K. b-Carbolines: metabolism and neurotoxicity. Biogenic Amines 1996, 12:171-180.
7. Collins MANeafsey E.J. Potential neurotoxic " agents provocateurs" in Parkinson's disease. Neurotoxicol Teratol 2002, 24:571-577.
8. Fujita M., Nishino H., Kumazaki M., Shimada S., Tohyama M., Nishimura T. Expression of dopamine transporter mRNA and its binding site in fetal nigral cells transplanted into the striatum of 6-OHDA lesioned rat. Mol Brain Res 1996, 39:127-136.
9. Hamann J., Rommelspacher H., Storch A., Reichmann H., Gille G. Neurotoxic mechanisms of 2,9-dimethyl-b-carbolinium ion in primary dopaminergic culture. J Neurochem 2006, 98:1185-1199.
10. Herraiz T., Chaparro C. Human monoamine oxidase is inhibited by tobacco smoke: beta-carboline alkaloids act as potent and reversible inhibitors. Biochem Biophys Res Commun 2005, 326:378-386.
11. Herraiz T. Identification and occurrence of the bioactive betacarbolines norharman and harman in coffee brews. Food Addit Contam 2002, 19:748-754.
12. Kim D.H., Jang Y.Y., Han E.S., Lee C.S. Protective effect of harmaline and harmalol against dopamine-and 6-hydroxydopamine-induced oxidative damage of brain mitochondria and synaptosomes, and viability loss of PC12 cells. Eur J Neurosci 2001, 13:1861-1872.
13. Kim H.H., Jang Y.Y., Han E.S., Lee C.S. Differential antioxidant effects of ambroxol, rutin, glutathione and harmaline. J Appl Pharmacol 1999, 7:112-120.
14. Kuhn W., Muller T., Grosse H., Rommelspacher H. Plasma harman and norharman in Parkinson's disease. J Neural Transm Suppl 1995, 46:291-295.
15. Kuhn W., Müller T.H., Grosse H., Rommelspacher H. Elevated levels of harman and norharman in cerebrospinal fluid of parkinsonian patients. J Neural Transm 1996, 103:1435-1440.
16. Kupsch A., Sautter J., Schwarz J., Riederer P., Gerlach M., Oertel W.H. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in non-human primates is antagonized by pretreatment with nimodipine at the nigral, but not at the striatal level. Brain Res 1996, 741(1-2):185-196.
17. Lee C.S., Han E.S., Jang Y.Y., Han J.H., Ha H.W., Kim D.E. Protective effect of harmalol and harmaline on MPTP neurotoxicity in the mouse and dopamine-induced damage of brain mitochondria and PC12 cells. J. Neurochem 2000, 75:521-531.
18. Loew G.H., Nienow J., Lawson J.A., Toll L., Uyeno E.T. Theoretical structure-activity studies of b-carboline analogs. Requirements for benzodiazepine receptor affinity and antagonist activity. Mol Pharmacol 1985, 28:17-31.
19. Lutes J., Lorden J.F., Beales M., Lotmans G.A. Tolerance to the tremorogenic effects of harmaline: evidence for altered olivo-cerebellar function. Neuropharmacology 1988, 27:849-855.
20. Maher P., Davis J.B. The role of monoamine metabolism in oxidative glutamate toxicity. Neuroscience 1996, 16:6394-6401.
21. Matsubara K., Aoyama K., Suno M., Awaya T. N-methylation underlying Parkinson's disease. Neurotoxicol Teratol 2002, 24:593-598.
22. Matsubara K., Gonda T., Sawada H., Uezono T., Kobayashi Y., Kawamura T., et al. Endogenously occurring b-carboline induces parkinsonism in nonprimate animals: A possible causative protoxin in idiopathic Parkinson's disease. J Neurochem 1998, 70:727-735.
23. Means A.R. Regulatory cascades involving calmodulin-dependent protein kinases. Mol Endocrinol 2000, 14:4-13.
24. Negre-Salvayre A., Salvayre R. UV-treated lipoproteins as a model system for the study of biological effects of lipid peroxides on cultured cells. Biochim Biophys Acta 1992, 1123:207-215.
25. Pavlovic S., Schulze G., Wernicke C., Bonnet R., Gille G., Badiali L., et al. 2,9-Dimethyl-b-carbolinium, a neurotoxin occuring in human brain, is an equipotent apoptotic inducer as 1-methyl-4-phenylpyridinium (MPP+). Neuroscience 2006, 139:1525-1537.
26. Paxinos G., Watson C. The rat brain in stereotaxic coordinates 2007, Academic Press, San Diego, CA. 6th ed.
27. Pfau W., Skog K. Exposure to beta-carbolines norharman and harman. J Chromatogr B Anal Technol Biomed Life Sci 2004, 802:115-126.
28. Rodnitzky R.L. Can calcium antagonists provide a neuroprotective effect in Parkinson's disease?. Drugs 1999, 57(6):845-849.
29. Shi C.C., Chen S.Y., Wang G.J., Liao J.F., Chen C.F. Vasorelaxant effect of harman. Eur J Pharmacol 2000, 390:319-325.
30. Splettstoesser F., Bonnet U., Wiemann M., Bingmann D., Sselberg D.B. Modulation of voltage-gated channel currents by harmaline and harmane. Br J Pharmacol 2005, 144:52-58.
31. Storch A., Hwang Y.-I., Gearhart D.A., Beach W., Neafsey E.J., Collins M.A., et al. Dopamine transporter-mediated cytotoxicity of β-carbolinium derivatives related to Parkinson's disease: relationship to transporter-dependent uptake. J Neurochem 2004, 89:685-694.
32. Sugimura T., Nagao M. Mutagenic factors in cooked foods. CRC Crit Rev Toxicol 1979, 6:189-209.
33. Surmeier D.J. Calcium, ageing, and neuronal vulnerability in Parkinson's disease. Lancet Neurol 2007, 6(10):933-938.
34. Tse S.Y.H., Mak I.T., Dickens B.F. Antioxidative properties of harmane and b-carboline alkaloids. Biochem Pharmacol 1991, 42:459-464.
35. 2+ signaling in rotenone-induced apoptosis in human neuroblastoma SH-SY5Y cells. Neurosci Lett 2005, 376:127-132.